Alfasigma to Acquire Intercept Pharmaceuticals to Expand into Liver Diseases
By Amit Kaushik
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 18 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2812 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to bolster its gastrointestinal and hepatology portfolio, Alfasigma has agreed to acquire Intercept for US$794 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS